JDQ-443 is a small molecule commercialized by Novartis, with a leading Phase III program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 6 clinical trials, of which 4 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of JDQ-443’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for JDQ-443 is expected to reach an annual total of $28 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
JDQ-443 is under development for the treatment of advanced solid tumor, small cell lung cancer, non-small cell lung cancer and colorectal cancer. It acts by targeting KRAS G12C mutation. It is administered through oral route. The drug candidate is a new molecular entity (NME).
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
The company reported revenues of (US Dollars) US$51,742 million for the fiscal year ended December 2022 (FY2022), a decrease of 2.1% over FY2021. The operating profit of the company was US$9,197 million in FY2022, compared to an operating profit of US$11,689 million in FY2021. The net profit of the company was US$6,955 million in FY2022, compared to a net profit of US$24,021 million in FY2021.
For a complete picture of JDQ-443’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.